Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization

Bibliographic Details
Title: Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization
Authors: Gloria Pedot, Joana Graça Marques, Philip P. Ambühl, Marco Wachtel, Stephanie Kasper, Quy A. Ngo, Felix K. Niggli, Beat W. Schäfer
Source: Neoplasia: An International Journal for Oncology Research, Vol 27, Iss , Pp 100784- (2022)
Publisher Information: Elsevier, 2022.
Publication Year: 2022
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Ewing sarcoma, EWS-FLI1, Protein stability, Fimepinostat, HDACi, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Oncogenic transcription factors lacking enzymatic activity or targetable binding pockets are typically considered “undruggable”. An example is provided by the EWS-FLI1 oncoprotein, whose continuous expression and activity as transcription factor are critically required for Ewing sarcoma tumor formation, maintenance, and proliferation. Because neither upstream nor downstream targets have so far disabled its oncogenic potential, we performed a high-throughput drug screen (HTS), enriched for FDA-approved drugs, coupled to a Global Protein Stability (GPS) approach to identify novel compounds capable to destabilize EWS-FLI1 protein by enhancing its degradation through the ubiquitin-proteasome system.The protein stability screen revealed the dual histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) inhibitor called fimepinostat (CUDC-907) as top candidate to modulate EWS-FLI1 stability. Fimepinostat strongly reduced EWS-FLI1 protein abundance, reduced viability of several Ewing sarcoma cell lines and PDX-derived primary cells and delayed tumor growth in a xenograft mouse model, whereas it did not significantly affect healthy cells. Mechanistically, we demonstrated that EWS-FLI1 protein levels were mainly regulated by fimepinostat's HDAC activity.Our study demonstrates that HTS combined to GPS is a reliable approach to identify drug candidates able to modulate stability of EWS-FLI1 and lays new ground for the development of novel therapeutic strategies aimed to reduce Ewing sarcoma tumor progression.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1476-5586
Relation: http://www.sciencedirect.com/science/article/pii/S1476558622000136; https://doaj.org/toc/1476-5586
DOI: 10.1016/j.neo.2022.100784
Access URL: https://doaj.org/article/f24c79f3904c4ff989ef5f1f94d4e53d
Accession Number: edsdoj.f24c79f3904c4ff989ef5f1f94d4e53d
Database: Directory of Open Access Journals
More Details
ISSN:14765586
DOI:10.1016/j.neo.2022.100784
Published in:Neoplasia: An International Journal for Oncology Research
Language:English